Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269246 | 1.00 | HRH3 (0.35) | HRH3HRH4HRH2HRH1PDK2 | |
| SCHEMBL30983550 | 0.97 | PDK2 (0.37) | HRH3HRH4PDK2PIK3CD | |
| SCHEMBL31269003 | 0.95 | HRH4 (0.36) | HRH3HRH4HRH2HRH1PDK2 | |
| SCHEMBL31268792 | 0.95 | HRH4 (0.35) | HRH3HRH4PIK3CD | |
| SCHEMBL31269384 | 0.92 | PDK2 (0.37) | HRH3HRH4HRH2HRH1PDK2 | |
| SCHEMBL31268906 | 0.92 | HRH3 (0.34) | HRH3HRH4HRH2HRH1PDK2 | |
| SCHEMBL31269094 | 0.91 | PDK2 (0.37) | HRH3HRH4PDK2PIK3CD | |
| SCHEMBL31269269 | 0.91 | DRD2 (0.33) | HRH4PIK3CD | |
| SCHEMBL31269258 | 0.89 | HRH4 (0.36) | HRH3HRH4PIK3CD | |
| SCHEMBL31268848 | 0.87 | HRH3 (0.35) | HRH3HRH4HRH2HRH1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |